Expand HURA Menu
HURA MENU

HURA Latest Press Releases

-- February 24, 2026 --

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences PRNewswire 5:20 PM

-- February 17, 2026 --

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers PRNewswire 7:45 AM

-- February 12, 2026 --

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PRNewswire 7:45 AM

-- February 2, 2026 --

TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma PRNewswire 7:45 AM

-- December 15, 2025 --

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone PRNewswire 7:50 AM

-- December 11, 2025 --

TuHURA Biosciences Provides Corporate Update Following Recent Financing PRNewswire 7:30 AM

-- December 9, 2025 --

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering PRNewswire 9:50 AM

-- December 8, 2025 --

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition PRNewswire 7:50 AM

-- November 14, 2025 --

TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update PRNewswire 7:00 AM

-- November 3, 2025 --

TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition PRNewswire 9:01 AM
Market Data Delayed 15 Minutes